Literature DB >> 9340250

[Lymphomatoid granulomatosis--remission induction with interferon-alpha 2b].

C Richter1, A Schnabel, K M Müller, M Reuter, P Schuster, W L Gross.   

Abstract

HISTORY AND ADMISSION
FINDINGS: A 72-year-old woman was admitted to hospital because of nonproductive cough, acrodistal sensorimotor axonal polyneuropathy, fatigue and 10 kg weight loss over the preceding 9 months. INVESTIGATIONS: Chest radiogram showed multiple round foci in both lungs. No organs other than the lungs and the peripheral nervous system were affected. Open lung biopsy revealed a pleomorphic angioinvasive lymphocytic infiltrations. DIAGNOSIS, TREATMENT AND COURSE: The findings indicated lymphomatoid granulomatosis (LG). Wegener granulomatosis was excluded on the basis of the clinical, serological and histopathological findings. Treatment with alpha-interferon (IFN-alpha) produced complete remission within 4 months. Interruption of treatment immediately resulted in a recurrence.
CONCLUSION: Together with previously reported cases this patient's response to IFN-alpha suggests that IFN-alpha is a less toxic alternative to cyclophosphamide and corticosteroid administration in the early stages of LG.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9340250     DOI: 10.1055/s-2008-1047734

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

Review 1.  [Lymphomatoid granulomatosis: differential diagnosis and therapy].

Authors:  M Bohle; K Rasche; K M Müller; G Schultze-Werninghaus; A Fisseler-Eckhoff
Journal:  Med Klin (Munich)       Date:  1999-09-15

2.  Lymphomatoid granulomatosis in a renal transplant patient.

Authors:  François Cachat; Kathleen Meagher-Villemure; Jean-Pierre Guignard
Journal:  Pediatr Nephrol       Date:  2003-06-12       Impact factor: 3.651

3.  Lymphomatoid granulomatosis involving the central nervous system: A case report and review of the literature.

Authors:  Hongli Liu; Jing Chen; Dandan Yu; Jianli Hu
Journal:  Oncol Lett       Date:  2014-03-28       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.